Modeling the interactions between osteoblast and osteoclast activities in bone remodeling

Journal of Theoretical Biology

Volumn 229, Issue 3, 2004, Pages 293-309

  Lemaire, Vincent ^a,b   Tobin, Frank L ^a   Greller, Larry D ^a,c   Cho, Carolyn R ^a,d   Suva, Larry J ^a,e  

^a GLAXOSMITHKLINE   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c Biosystemix Ltd   (Canada)

^d Predix Pharmaceuticals   (United States)

^e UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Bone cells; Differentiation; Mathematical modeling; Osteoporosis; Parathyroid hormone; Therapeutic strategies

Indexed keywords

ANABOLIC AGENT; GLUCOCORTICOID;

BONE; NUMERICAL MODEL;

ARTICLE; BEHAVIOR; BONE DISEASE; BONE REGENERATION; BONE REMODELING; BONE STRUCTURE; BONE TISSUE; CATABOLISM; CELL ACTIVITY; CELL DIFFERENTIATION; CELL INTERACTION; ESTROGEN DEFICIENCY; HUMAN; MATHEMATICAL MODEL; METABOLIC BONE DISEASE; MONOTHERAPY; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; PRIORITY JOURNAL; SENESCENCE; VITAMIN D DEFICIENCY;

BONE DISEASES, METABOLIC; BONE REMODELING; CELL COMMUNICATION; HUMANS; MODELS, BIOLOGICAL; OSTEOBLASTS; OSTEOCLASTS; PARATHYROID HORMONE;

EID: 3042548087     PISSN: 00225193     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtbi.2004.03.023     Document Type: Article

References (94)

1. Adelina C.M., Fernandes M.H. Long-term effects of parathyroid hormone, 1, 25-dihydroxyvitamin d(3), and dexamethasone on the cell growth and functional activity of human osteogenic alveolar bone cell cultures. Pharmacol. Res. 42(4):2000;345-353
2. Akamine T., et al. Prostaglandin E2 prevents bone loss and adds extra bone to immobilized distal femoral metaphysis in female rats. Bone. 13(1):1992;11-22
3. Alliston T., Choy L., et al. TGF-beta-induced repression of CBFA1 by Smad3 decreases cbfa1 and osteocalcin expression and inhibits osteoblast differentiation. Embo J. 20(9):2001;2254-2272
4. Aubin J.E. Advances in the osteoblast lineage. Biochem. Cell Biol. 76(6):1998;899-910
5. Aubin J.E. Bone stem cells. J. Cell. Biochem. 30-31(Suppl):1998;73-82
6. Aubin J.E., Bonnelye E. Osteoprotegerin and its ligand. a new paradigm for regulation of osteoclastogenesis and bone resorption Medscape Womens Health. 5(2):2000;5
7. Barou O., Palle S., et al. Hindlimb unloading in rat decreases preosteoblast proliferation assessed in vivo with BrdU incorporation. Am. J. Physiol. 274(1 Pt 1):1998;E108-114
8. Bland R. Steroid hormone receptor expression and action in bone. Clin. Sci. 98(2):2000;217-240
9. Bonewald L.F., Dallas S.L. Role of active and latent transforming growth factor beta in bone formation. J. Cell. Biochem. 55(3):1994;350-357
10. Boyce B.F., Hughes D.E., et al. Recent advances in bone biology provide insight into the pathogenesis of bone diseases. Lab. Invest. 79(2):1999;83-94
11. Brandstrom H., Bjorkman T., et al. Regulation of osteoprotegerin secretion from primary cultures of human bone marrow stromal cells. Biochem. Biophys. Res. Commun. 280(3):2001;831-835
12. Burgess T.L., Qian Y., et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J. Cell Biol. 145(3):1999;527-538
13. Canalis E., Giustina A. Glucocorticoid-induced osteoporosis. summary of a workshop J. Clin. Endocrinol. Metab. 86(12):2001;5681-5685
14. Carmeliet G., Vico L., et al. Space flight. a challenge for normal bone homeostasis Crit. Rev. Eukaryot. Gene. Exp. 11(1-3):2001;131-144
15. Chang D.J., Ji C., et al. Reduction in transforming growth factor beta receptor I expression and transcription factor CBFa1 on bone cells by glucocorticoid. J. Biol. Chem. 273(9):1998;4892-4896
16. Cho, C., Greller, L., et al., 2000. Parathyroid hormone receptor and osteoporosis - towards target validation by mathematical modeling. King of Prussia, PA, USA, Bioinformatics Mathematical Biology, Bone & Cartilage Biology, SmithKline Beecham Pharmaceuticals R&D.
17. Chung H., Kang Y.S., et al. Deflazacort increases osteoclast formation in mouse bone marrow culture and the ratio of RANKL/OPG mRNA expression in marrow stromal cells. J. Korean. Med. Sci. 16(6):2001;769-773
18. Collin-Osdoby P., Rothe L., et al. Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J. Biol. Chem. 276(23):2001;20659-20672
19. Compston J.E., Watts N.B. Combination therapy for postmenopausal osteoporosis. Clin. Endocrinol. (Oxf). 56(5):2002;565-569
20. Dempster D.W., Cosman F., et al. Anabolic actions of parathyroid hormone on bone (published erratum appears in Endocr. Rev. 1994;15(2):261). Endocr. Rev. 14(6):1993;690-709
21. Du P., Ye Y., et al. Endogenous parathyroid hormone-related peptide enhances proliferation and inhibits differentiation in the osteoblast-like cell line ROS 17/2.8. Bone. 26(5):2000;429-436
22. Ducy P., Schinke T., et al. The osteoblast. a sophisticated fibroblast under central surveillance Science. 289(5484):2000;1501-1504
23. Engelborghs, K., Luzyanina, T., et al., 2001. DDE-BIFTOOL: a Matlab package for bifurcation analysis of delay differential equations. Leuven, Belgium, Department of Computer Sciences, Free University.
24. Eriksen E.F., Kassem M. The cellular basis of bone remodeling. Triangle. 31(2/3):1992;45-57
25. Feldman D. Vitamin D, parathyroid hormone, and calcium. a complex regulatory network Am. J. Med. 107(6):1999;637-639
26. Filvaroff E., Derynck R. Bone remodelling. a signalling system for osteoclast regulation Curr. Biol. 8(19):1998;R679-R682
27. Finkelstein, J.S., 1996. Pharmacological mechanisms of therapeutics: parathyroid hormone. Principles of Bone Biology, Academic Press, New York (Chapter 71) 993-1005.
28. Frost H.M. The skeletal intermediary organization. Metab. Bone Dis. Relat. Res. 4(5):1983;281-290
29. Fujimori A., Cheng S.L., et al. Dissociation of second messenger activation by parathyroid hormone fragments in osteosarcoma cells. Endocrinology. 128(6):1991;3032-3039
30. Goltzman D. Interactions of PTH and PTHrP with the PTH/PTHrP receptor and with downstream signaling pathways. exceptions that provide the rules [editorial; comment] J. Bone Mineral Res. 14(2):1999;173-177
31. Greenfield E.M., Bi Y., et al. Regulation of osteoclast activity. Life Sci. 65(11):1999;1087-1102
32. Gunther T., Schinke T. Mouse genetics have uncovered new paradigms in bone biology. Trends Endocrinol. Metab. 11(5):2000;189-193
33. Halladay D.L., Miles R.R., et al. Identification of signal transduction pathways and promoter sequences that mediate parathyroid hormone 1-38 inhibition of osteoprotegerin gene expression. J. Cell Biochem. 84(1):2001;1-11
34. Hauschka, P.V., 1989. Growth factors effects. In: Hall, B.K. (Ed.), Bone, Vol. 1. CRC Press, Boca Raton, FL, 512pp.
35. Hofbauer L.C., Dunstan C.R., et al. Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. Biochem. Biophys. Res. Commun. 250(3):1998;776-781
36. Hofbauer L.C., Gori F., et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells. potential paracrine mechanisms of glucocorticoid-induced osteoporosis [see comments] Endocrinology. 140(10):1999;4382-4389
37. Hofbauer L.C., Khosla S., et al. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology. 140(9):1999;4367-4370
38. Hofbauer L.C., Khosla S., et al. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J. Bone Mineral Res. 15(1):2000;2-12
39. Hofbauer L.C., Neubauer A., et al. Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin. potential implications for the pathogenesis and treatment of malignant bone diseases Cancer. 92(3):2001;460-470
40. Hofbauer L.C., Shui C., et al. Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. Biochem. Biophys. Res. Commun. 280(1):2001;334-339
41. Huang W.H., Zheng M.H. Steroid hormones and bone. Histol. Histopathol. 14(4):1999;1257-1268
42. Isogai Y., Akatsu T., et al. Parathyroid hormone regulates osteoblast differentiation positively or negatively depending on the differentiation stages. J. Bone Mineral Res. 11(10):1996;1384-1393
43. Jee W.S., Wronski T.J., et al. Effects of spaceflight on trabecular bone in rats. Am. J. Physiol. 244(3):1983;R310-R314
44. Jerome C.P., Burr D.B., et al. Treatment with human parathyroid hormone (1-34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (macaca fascicularis). Bone. 28(2):2001;150-159
45. Jilka R.L., Weinstein R.S., et al. Osteoblast programmed cell death (apoptosis). modulation by growth factors and cytokines J. Bone Mineral Res. 13(5):1998;793-802
46. Jilka R.L., Weinstein R.S., et al. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J. Clin. Invest. 104(4):1999;439-446
47. Kahn, A., Gibbons, R., et al., 1995. Age-related bone loss. A hypothesis and initial assessment in mice. Clin. Orthop. (313) 69-75.
48. Kitazawa R., Imai Y., et al. Effects of continuous infusion of parathyroid hormone and parathyroid hormone-related peptide on rat bone in vivo. comparative study by histomorphometry Bone Mineral. 12(3):1991;157-166
49. Knauer D.J., Wiley H.S., et al. Relationship between epidermal growth factor receptor occupancy and mitogenic response. Quantitative analysis using a steady state model system. J. Biol. Chem. 259(9):1984;5623-5631
50. Komarova S.V., Smith R.J., et al. Mathematical model predicts a critical role for osteoclast autocrine regulation in the control of bone remodeling. Bone. 33(2):2003;206-215
51. Komori T., Yagi H., et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell. 89(5):1997;755-764
52. Kroll M.H. Parathyroid hormone temporal effects on bone formation and resorption. Bull. Math. Biol. 62(1):2000;163-188
53. Lacey D.L., Timms E., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 93(2):1998;165-176
54. Lauffenburger D.A., Linderman J.J. Receptors. Models for Binding, Trafficking, and Signaling:1996;Oxford University Press, New York; Toronto
55. Lowik C.W., van Leeuwen J.P., et al. A two-receptor model for the action of parathyroid hormone on osteoblasts. a role for intracellular free calcium and cAMP Cell Calc. 6(4):1985;311-326
56. Ma Y., et al. Partial maintenance of extra cancellous bone mass by antiresorptive agents after discontinuation of human parathyroid hormone (1-38) in right hindlimb immobilized rats. J. Bone Mineral Res. 10(11):1995;1726-1734
57. Ma Y.L., Cain R.L., et al. Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology. 142(9):2001;4047-4054
58. Manolagas S.C. Birth and death of bone cells. basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis Endocr. Rev. 21(2):2000;115-137
59. Marie P. Growth factors and bone formation in osteoporosis. roles for IGF-I and TGF-beta Rev. Rhum. Engl. Ed. 64(1):1997;44-53
60. Martin T.J., Ng K.W. Mechanisms by which cells of the osteoblast lineage control osteoclast formation and activity. J. Cell. Biochem. 56(3):1994;357-366
61. Meng X.W., Liang X.G., et al. Temporal expression of the anabolic action of PTH in cancellous bone of ovariectomized rats. J. Bone Mineral Res. 11(4):1996;421-429
62. Mosekilde L., Reeve J. Treatment with PTH peptides. Marcus R., Feldman D., Kelsey J. Osteoporosis. 1996;1293-1311 Academic Press, New York. (Chapter 68)
63. Mundy G.R. Cellular and molecular regulation of bone turnover. Bone. 24(5 Suppl):1999;35S-38S
64. Mundy G.R., Boyce B.F., et al. Cytokines and bone remodeling. Marcus R., Feldman D., Kelsey J. Osteoporosis. 1996;301-313 Academic Press, New York. (Chapter 11)
65. Neer R.M., Arnaud C.D., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 344(19):2001;1434-1441
66. Nicolas V., Prewett A., et al. Age-related decreases in insulin-like growth factor-I and transforming growth factor-beta in femoral cortical bone from both men and women. implications for bone loss with aging J. Clin. Endocrinol. Metab. 78(5):1994;1011-1016
67. Parfitt A.M. The actions of parathyroid hormone on bone. relation to bone remodeling and turnover, calcium homeostasis, and metabolic bone diseases. II. PTH and bone cells: bone turnover and plasma calcium regulation Metabolism. 25(8):1976;909-955
68. Parfitt A.M., Mundy G.R., et al. A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates. J. Bone Mineral Res. 11(2):1996;150-159
69. Rattanakul C., Lenbury Y., et al. Modeling of bone formation and resorption mediated by parathyroid hormone. response to estrogen/PTH therapy Biosystems. 70(1):2003;55-72
70. Riggs B.L., Khosla S., et al. Sex steroids and the construction and conservation of the adult skeleton. Endocr. Rev. 23(3):2002;279-302
71. Rodan G.A. Coupling of bone resorption and formation during bone remodeling. Marcus R., Feldman D., Kelsey J. Osteoporosis. 1996;289-299 Academic Press, New York. (Chapter 10)
72. Rodan G.A. Control of bone formation and resorption. biological and clinical perspective J. Cell. Biochem. 30-31(Suppl):1998;55-61
73. Rodan G.A., Martin T.J. Role of osteoblasts in hormonal control of bone resorption - a hypothesis. Calc. Tissue Int. 33(4):1981;349-351
74. Rodan G.A., Martin T.J. Therapeutic approaches to bone diseases. Science. 289(5484):2000;1508-1514
75. Roodman G.D. Cell biology of the osteoclast. Exp. Hematol. 27(8):1999;1229-1241
76. Rubin M.R., Bilezikian J.P. Clinical review 151. the role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: a re-examination of the evidence J. Clin. Endocrinol. Metab. 87(9):2002;4033-4041
77. Sasaki N., Kusano E., et al. Glucocorticoid decreases circulating osteoprotegerin (OPG). possible mechanism for glucocorticoid induced osteoporosis Nephrol. Dial. Transplant. 16(3):2001;479-482
78. Seeman, E., Delmas, P.D., 2001. Reconstructing the skeleton using intermittent parathyroid hormone. Trends Endocrinol. Metab.
79. Siegel P.M., Massague J. Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat. Rev. Cancer. 3(11):2003;807-821
80. Simmons, D.J., Grynpas, M.D., 1990. Mechanisms of bone formation in vivo. In: Hall, B.K. (Ed.), Bone, Vol. I, A Treatrise. CRC Press, Boca Raton, FL.
81. Simonet W.S., Lacey D.L., et al. Osteoprotegerin. a novel secreted protein involved in the regulation of bone density Cell. 89(2):1997;309-319
82. Slatopolsky E., Dusso A., et al. New analogs of vitamin D3. Kidney Int. (Suppl. ). 73:1999;S46-S51
83. Tam C.S., Heersche J.N., et al. Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action. differential effects of intermittent and continuous administration Endocrinology. 110(2):1982;506-512
84. Teitelbaum S.L. Bone resorption by osteoclasts. Science. 289(5484):2000;1504-1508
85. Thomas G.P., et al. Changing RANKL/OPG mRNA expression in differentiating murine primary osteoblasts. J. Endocrinol. 170(2):2001;451-460
86. Titus L., Jackson E., et al. 1, 25-dihydroxyvitamin D reduces parathyroid hormone receptor number in ROS 17/2.8 cells and prevents the glucocorticoid-induced increase in these receptors. relationship to adenylate cyclase activation J. Bone Mineral Res. 6(6):1991;631-637
87. Turner R.T., Evans G.L., et al. Spaceflight results in depressed cancellous bone formation in rat humeri. Aviat. Space Environ. Med. 66(8):1995;770-774
88. Uzawa T., Hori M., et al. Comparison of the effects of intermittent and continuous administration of human parathyroid hormone(1-34) on rat bone. Bone. 16(4):1995;477-484
89. van Leeuwen J.P., van Driel M., et al. Vitamin D control of osteoblast function and bone extracellular matrix mineralization. Crit. Rev. Eukaryot. Gene. Expr. 11(1-3):2001;199-226
90. Viereck V., Emons G., et al. Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem. Biophys. Res. Commun. 291(3):2002;680-686
91. Watson P.H., Fraher L.J., et al. Enhanced osteoblast development after continuous infusion of hPTH(1-84) in the rat. Bone. 24(2):1999;89-94
92. Weinstein R.S. Glucocorticoid-induced osteoporosis. Rev. Endocr. Metab. Disord. 2(1):2001;65-73
93. Whitfield J.F., Morley P., et al. Bone growth stimulators. New tools for treating bone loss and mending fractures. Vitam. Horm. 65:2002;1-80
94. Xie L.Y., Leung A., et al. Downregulation of the PTH/PTHrP receptor by vitamin D3 in the osteoblast-like ROS 17/2.8 cells. Am. J. Physiol. 270(4 Pt 1):1996;E654-E660